PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma

Neurology
Sylvia C KurzPatrick Y Wen

Abstract

To investigate the question of whether salvage therapy with the programmed cell death protein 1 (PD-1)-blocking antibodies nivolumab or pembrolizumab with or without bevacizumab offers clinical or survival benefit in patients with recurrent high-grade gliomas (HGGs). This was a single-institution retrospective observational study in 31 adult patients who received pembrolizumab (Keytruda) or nivolumab (Opdivo) with or without concurrent bevacizumab for recurrent high-grade glioma. Median progression-free survival (mPFS) from first anti-PD-1 dose was 3.2 months (95% confidence interval [CI] 2.2-4.2), and there was no difference in patients receiving nivolumab (mPFS 3.8 months, 95% CI 1.7-5.8) compared to patients receiving pembrolizumab (mPFS 2.3 months, 95% CI 1.7-2.8, log rank 3.1, p = 0.08). There was also no difference in mPFS if patients had previously received bevacizumab (mPFS 3.2 months, 95% CI 2-4.3) or were bevacizumab naive (mPFS 3.7, 95% CI 0-7.9, log rank 1.3, p = 0.3). The median survival from date of first anti-PD-1 dose was 6.6 months (95% CI 4.2-9.1). Salvage therapy with nivolumab or pembrolizumab with or without bevacizumab does not confer a survival benefit in this heavily pretreated unselected patient populat...Continue Reading

References

Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric BouffetUri Tabori
Jul 6, 2016·Journal of Neuro-oncology·Deborah T BlumenthalFelix Bokstein
Apr 26, 2017·Expert Review of Anticancer Therapy·Thomas HundsbergerPatrick Y Wen
May 14, 2017·Journal of Neuro-oncology·Marc C Chamberlain, Bryan T Kim
Dec 20, 2017·Journal for Immunotherapy of Cancer·Samantha N ReissChristian Grommes

❮ Previous
Next ❯

Citations

Apr 11, 2019·International Journal of Immunopathology and Pharmacology·Marco Flavio Michele VismaraGiuseppe Donato
Apr 27, 2019·Neurochemical Research·Thomas N SeyfriedPurna Mukherjee
Apr 10, 2020·Future Oncology·Vincenzo Di NunnoAlba Ariela Brandes
Feb 14, 2020·Acta Neuropathologica Communications·Matthew McCordCraig Horbinski
May 27, 2020·JAMA : the Journal of the American Medical Association·Alexandra M Miller, Lisa M DeAngelis
Jun 25, 2020·JAMA : the Journal of the American Medical Association·Ameet SarpatwariAaron S Kesselheim
Jul 10, 2020·Human Vaccines & Immunotherapeutics·Tianrui YangWenbin Ma
Sep 5, 2020·The Journal of International Medical Research·Can ChenYanling Zhang
Jan 29, 2019·Frontiers in Pharmacology·Ruo Qiao ChenXiao Qian Chen
Jun 7, 2019·Expert Opinion on Therapeutic Targets·Rajan PatelGanesh Rao
Jul 10, 2020·Neuro-oncology Advances·Caterina BrighiSimon Puttick
Nov 24, 2020·Expert Review of Neurotherapeutics·Erin CrottyHideho Okada
Dec 17, 2020·Frontiers in Genetics·Yang YuanMao Qing
Jun 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erik LadomerskyDerek A Wainwright
Jan 28, 2021·Immunity, Inflammation and Disease·Haitao LuoXingen Zhu
Jan 15, 2021·World Neurosurgery·Guorong YangLing Qin
Jan 1, 2021·BioMed Research International·Pan LiaoHonglan Qu
Feb 14, 2021·International Immunopharmacology·Abolfazl MaghrouniAmirhossein Sahebkar
Mar 31, 2021·Neurosurgery Clinics of North America·Nalin LeelatianRanjit S Bindra

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.